Abstract
Many countries affected by the global outbreak of monkeypox in 2022 have observed a decline in cases. Our mathematical model incorporating empirical estimates of the heavy-tailed sexual partnership distribution among men who have sex with men (MSM) suggests that monkeypox epidemics can hit the infection-derived herd immunity threshold and begin to decline with less than 1% of sexually active MSM population infected regardless of interventions or behavioural changes. Consistently, we found that many countries and US states experienced an epidemic peak with cumulative cases of around 0.1–0.7% of MSM population. The observed decline in cases may not necessarily be attributable to interventions or behavioural changes primarily, although continuing these approaches in the most effective manner is still warranted to minimise total epidemic size.
Competing Interest Statement
AE received a research grant from Taisho Pharmaceutical Co., Ltd. for research outside this study.
Funding Statement
AE and FM are supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (to AE, grant number: 22K17329 and to FM, 20J00793), JSPS Overseas Research Fellowships (to AE). AE and HM are supported by foundation for the Fusion Of Science and Technology (to AE). SF and SA are supported by Wellcome Trust (to SF, 210758/Z/18/Z). CABP is supported by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC3 (800176); this Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. S-mJ is supported by the Centers for Disease Control and Prevention (CDC) SHEPheRD (200-2016-91781). EF is supported by the Medical Research Council, United Kingdom Research and Innovation (MRC-UKRI), MR/S020462/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are publicly available
